Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferred treatment for intermediate to advanced stage non-small cell lung cancer (NSCLC) in patients with EGFR gene mutation [1, 2]. Here, EGFR is linked to non-small cell lung carcinoma.